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Background: The literature on the epidemiology, mortality and treatment of pandrug-resistant 22 
(PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. 23 
Objective: To consolidate the relevant literature and identify treatment options for PDR GNB 24 
infections. 25 
Methods: A systematic search in MEDLINE, Scopus and clinical trial registries was conducted. 26 
Studies reporting PDR clinical isolates were eligible for review if susceptibility testing for all 27 
major antimicrobials had been performed. Characteristics and findings of retrieved studies were 28 
qualitatively synthesized. 29 
Results: Of 81 studies reviewed, 47 (58%) were published in the last 5 years. The reports 30 
reflected a worldwide dissemination of PDR GNB in 25 countries in 5 continents. Of 526 PDR 31 
isolates reported, Pseudomonas aeruginosa (n=175), Acinetobacter baumannii (n=172) and 32 
Klebsiella pneumoniae (n=125) were most common. PDR GNB were typically isolated in intensive 33 
care units, but several studies demonstrated wider outbreak potential, including dissemination 34 
to long-term care facilities and international spread. All-cause mortality was high (range, 20%-35 
71%), but appeared to be substantially reduced in studies reporting treatment regimens active 36 
in vitro. No controlled trial has been performed to date, but several case reports and series 37 
noted successful use of various regimens, predominantly synergistic combinations, and in 38 
selected patients increased exposure regimens and newer antibiotics. 39 
Conclusion: PDR GNB are increasingly being reported worldwide and are associated with high 40 
mortality. Several treatment regimens have been successfully used, of which synergistic 41 
combinations appear to be most promising and often the only available option. More 42 
pharmacokinetic/pharmacodynamic and outcome studies are needed to guide the use of 43 
synergistic combinations.  44 
 45 
Mathematical prediction models estimated that thousands of extra deaths are attributable to 46 
MDR bacterial infections every year in Europe. 1 However, the mortality attributable to XDR and 47 
pandrug-resistant (PDR) infections appears to be much lower based on real-life data from a 48 
recent study in France. 1 In contrast, an alarming increase in the incidence of PDR infections, 49 
most frequently caused by PDR Acinetobacter baumannii, has been detected in the authors 50 
region 2 and has been associated with high mortality. 3 In view of such controversial findings, 51 
studying the worldwide epidemiology of pandrug resistance becomes especially important. 52 
Furthermore, studies on the treatment of PDR infections are scarce and scattered 4, 5 and 53 
clinicians often resort to salvage treatments, including the use of antimicrobial combinations 54 
or antibiotics for non-approved indications, with questionable dosing and administration route. 6  55 
This review aims to systematically search and consolidate the literature on the epidemiology, 56 
mortality and treatment of PDR Gram-negative bacteria (GNB). Particularly, considering the 57 
controversies described above, we examined the geographical dissemination of PDR GNB and 58 
the mortality associated with PDR GNB infections. Furthermore, the several treatment options 59 
that have been reported to be effective against PDR GNB infections were summarized and their 60 
potential to reduce mortality was assessed. 61 
 62 
This systematic review complies with the Preferred Reporting Items for Systematic Reviews and 63 
Meta-Analyses (PRISMA) statement. 7  64 
Search strategy: We conducted the following search in MEDLINE and Scopus, from inception to 65 
May 2019: panresistant OR panresistance OR "pan-resistant" OR "pan resistant" OR pandrug OR 66 
pan-drug OR "pandrug-resistant" OR "pan-drug-resistant" OR "therapeutic dead end" OR 67 
"therapeutic impasse". Retrieved articles were screened for relevance based on their title and 68 
abstract. The full-text of potentially eligible articles was then reviewed. The search was 69 
supplemented by reference tracking of included papers. Additionally, we used the same search 70 
terms in clinical trial registries (International Clinical Trial Registry Platform, Cochrane Central 71 
Register of Controlled Trials, ClinicalTrials.gov, Australia and New Zealand Clinical Trials Registry, 72 
International Standard Randomised Controlled Trial Number, European Clinical Trials Database) to 73 
identify trials assessing the management of PDR infections. 74 
Eligibility criteria: We included all types of studies providing information regarding the 75 
epidemiology, prognosis and treatment of PDR GNB isolated from clinical samples in healthcare 76 
settings. We used the definition and list of antimicrobial agents proposed by Magiorakos et al 8 77 
plus tigecycline for A. baumannii to define PDR. We included studies reporting at least one PDR 78 
isolate in which susceptibility testing was performed for at least one agent in each of the 79 
following antimicrobial categories (with the exception of intrinsic resistance to these agents): 80 
carbapenems, polymyxins, aminoglycosides, and glycylcyclines (tigecycline). Eligibility of non-81 
English language studies was assessed based on their English title and abstract. When necessary, 82 
the full-text was translated in English using Google Translate. 83 
Data items and collection process: The following data were collected: study design, country, 84 
time period, bacterial species, list of antibiotics used for susceptibility testing, criteria used to 85 
define susceptibility breakpoints, method of susceptibility testing for colistin and tigecycline, 86 
breakpoint used for susceptibility to tigecycline, number of PDR isolates, proportion PDR (of all 87 
examined isolates), treatment regimens and outcomes (both clinical and microbiological) of 88 
infections caused by PDR GNB. Reports of the same isolate in more than one studies were 89 
counted only once. Data extraction was carried out by the first author.  90 
Exploration of the activity of newer agents: Because few relevant studies were found in our 91 
main search, we expanded the search in MEDLINE (PubMed) with the following terms: 92 
plazomicin OR eravacycline OR vaborbactam OR (avibactam AND aztreonam) OR (ceftazidime 93 
AND avibactam) OR ceftolozane. Only studies reporting the activity of these agents against GNB 94 
resistant to all other antimicrobials were included. 95 
Risk of bias: We assessed the completeness of the list of antimicrobials used for defining PDR 96 
and the method of susceptibility testing focusing on polymyxins and taking into account that 97 
broth microdilution is the only currently recommended method 9. In interpreting the proportion 98 
PDR, we took into account the populations studied and the fact that studies that did not report 99 
any PDR isolate were excluded from the review. We also considered the geographical 100 
distribution of possible PDR isolates from non-eligible studies. For studies reporting patient 101 
outcome, we examined the definition of outcome, the length of follow-up and whether 102 
mortality was attributable to the infection. In studies reporting treatment regimens, we 103 
recorded their design and whether patients with polymicrobial infections were included.  104 
Synthesis of results: We conducted a qualitative presentation and synthesis of the 105 
characteristics and findings of retrieved studies. Because of substantial clinical heterogeneity, a 106 
meta-analysis was not pursued. 107 
 108 
Study selection 109 
A flow chart of our review is depicted in Figure 1. A flow chart focused on the non-English 110 
language literature is depicted in Supplementary Figure 1.  111 
Study characteristics  112 
A total of 81 studies were eligible for this review, whose main characteristics are summarized in 113 
Supplementary Tables 1 to 3. The earliest study was published in 2004. Most studies (n=73; 114 
90%) were published within the last decade; more than half (n=47) were published in the last 5 115 
years and about a third (n=28) in the last 2 years. The proportion PDR among clinical isolates 116 
was available in 44 (54%) studies. 1, 10-51 All-cause mortality was reported in 33 (41%) 1, 4, 5, 20, 24, 35-117 
37, 51-75 studies. Treatment regimens were reported in 26 (32%) studies. 4, 5, 24, 37, 49, 51-55, 57, 58, 60, 63-66, 118 
68-72, 75, 76 119 
Definition of PDR  120 
Susceptibility testing for the full list of antimicrobial agents as recommended in consensus 121 
definitions 8 was reported in only 6 (7%) studies. 32, 34, 40, 59, 77-79 Antimicrobials for which 122 
susceptibility testing was most frequently not reported were; fosfomycin, older generation 123 
tetracyclines (such as minocycline), aminoglycosides (missing at least one aminoglycoside), 124 
trimethoprim/sulfamethoxazole, and ampicillin/sulbactam (for A. baumannii) (Supplementary 125 
Table 4). Isolates with intermediate susceptibility were interpreted as non-susceptible in most 126 
studies (n=53, 65%). In 14 (17%) studies 49, 52, 54-59, 61, 63, 64, 69, 71, 80 none of the isolates had 127 
intermediate susceptibilities, while in 14 (17%) other studies 16, 17, 28, 37, 38, 43, 46, 48, 50, 51, 62, 68, 74, 81 128 
the interpretation of intermediate susceptibility was not clarified. Broth microdilution to assess 129 
susceptibility to colistin was used in only 26 (32%) studies. 4, 10-12, 14, 15, 18, 22, 27, 29-32, 37, 42, 50, 56, 59, 61, 66, 130 
68, 69, 78, 80, 82, 83 The EUCAST contemporary susceptibility breakpoints for tigecycline (MIC>1mg/L), 131 
were used in 13 (16%) studies, 11, 13, 18, 22, 29, 30, 33, 42, 45, 49, 52, 67, 69 while FDA breakpoints (MIC>2mg/L 132 
or FDA disc diffusion breakpoints) were used in 11 (14%) studies. 4, 16, 19-21, 23, 27, 35, 38, 43, 84 In 18 133 
(22%) studies exact MICs were reported, 5, 49, 50, 56, 57, 59, 61, 63, 64, 66, 67, 69, 71, 77-80, 82 with almost all 134 
isolates having MICs>2mg/L. 135 
Epidemiology of PDR 136 
A total of 526 PDR GNB clinical isolates were reported in 25 countries in 5 continents (Table 1), 137 
reflecting a worldwide distribution. Although the ward of isolation was not reported for 59% 138 
(n=311) of all PDR isolates, at least 37% (n=194) were isolated from ICU patients. Nevertheless, 139 
several studies demonstrated the potential of PDR pathogens to cause outbreaks, involving both 140 
intra-hospital 38, 65, 73 and inter-hospital dissemination, 61 spread between hospitals and long-141 
term care facilities, 38, 67 and international spread even to countries with a low rate of resistant 142 
pathogens. 56, 67, 79  143 
The most common PDR species were Pseudomonas aeruginosa (n=175, 33%), Acinetobacter 144 
baumannii (n=172, 33%) and Klebsiella pneumoniae (n=125, 24%). Other less common PDR 145 
pathogens included Providencia stuartii (n=16),27, 65 Serratia marcescens (n=8), 22, 77 Enterobacter 146 
spp (n=6), 21 Burkholderia spp (n=6), 1, 21, 55 Chryseobacterium indologenes (n=5), 21, 54 147 
Elizabethkingia meningoseptica (n=3), 21 Morganella morganii (n=2), 21 and Escherichia coli 148 
(n=1). 21  149 
The proportion PDR of examined isolates was highly variable (ranging from 0.01% to 21%) 150 
among reviewed studies, reflecting their heterogeneity in terms of bacterial species, 151 
geographical locations, patient populations and types of infection or culture sites. For example, 152 
PDR proportion ranged from 0.01% to 0.20% in large (>3000 patients) multicenter studies 153 
involving diverse patient populations, 13, 23, 27, 29, 31, 42, 83 but was much higher (0.65% to 11%) in 154 
studies of intensive care unit (ICU) patients, 15, 19, 28, 36, 44 and in studies that focused on MDR (3% 155 
45), on carbapenem-resistant (5.7%, 11 13.3%, 22 2%, 32 7.7% 49), on XDR (10.8%, 20 4.7%, 16 6.5%,  156 
35 17.7%, 33 3.7% 37), or on colistin-resistant isolates (13.9% 18).  157 
Prognosis of infections by PDR 158 
All-cause mortality was examined in 142 patients with PDR GNB infection. 1, 4, 5, 20, 24, 35-37, 49, 51-74, 76 159 
To assess mortality in these studies the patients were followed for variable lengths of time; 28 160 
or 30 days 1, 4, 5, 35, 36 or until discharge from the ward or the hospital. 24, 37, 52-57, 59, 60, 63-72, 75 161 
Summing the data from all studies, all-cause mortality in PDR GNB infection was 53% (n=75 of 162 
142) but highly variable; excluding studies with < 5 patients, all-cause mortality ranged from 163 
20% to 71%. 4, 5, 20, 35, 36, 51, 65, 73-75 Mortality was high irrespective of infecting pathogen or site of 164 
infection, ranging from about 20% in urinary tract infections to >40% in other sites (Table 2). 165 
Among the 75 reported deaths, mortality was judged by the authors to be directly attributable 166 
to the infection in 11 cases, 20, 52, 56, 61, 62, 67, 71, 73, 75 but there were at least 6 deaths known to be 167 
unrelated to the PDR infection 5, 57, 60, 68, 72 and for the rest of the cases this was not discussed.   168 
Comparison of the mortality in PDR GNB infections to that in XDR GNB infections was possible in 169 
4 small-scale studies, and mortality was substantially higher for the former in all of them (71% vs 170 
55%, 20 67% vs 57%, 36 67% vs 30%, 35 and 36% vs 23% 5). However, differences were not 171 
statistically significant in individual studies, and confounding factors such as the severity of 172 
underlying condition or comorbidities, the site of infection and use of different treatment 173 
regimens used were not considered. 174 
All-cause mortality was very high (43/61 patients, 71%) with treatment regimens inactive in 175 
vitro, 24, 28, 39, 40, 55, 58, 73, 74, 77 but was substantially lower (19 /61 patients, 31%) with regimens that 176 
were confirmed to be active in vitro, mainly involving synergistic combinations. 4, 5, 37, 52, 53, 55, 57, 58, 177 
60, 63-66, 68-70, 73 178 
Treatment regimens 179 
We did not find any completed or ongoing clinical trials on the treatment of PDR GNB infections. 180 
The only available data come from 26 studies, exclusively case series or case reports, involving 181 
n=105 patients; K. pneumoniae n=31,  5, 49, 52, 53, 57, 63, 64, 66, 68, 69, 71 P. aeruginosa n=45, 37, 51, 58, 60, 70, 182 
72, 73, 75, 76 A. baumannii n=11, 4, 24 Providencia stuartii n=15, 65 Chryseobacterium indologenes n=2 183 
54, Burkholderia cepacia n=1. 55. In 8 of the 26 studies, polymicrobial infections or patients with 184 
concurrent infections by other bacteria in other sites were included. 35-37, 57, 70, 73-75 185 
Treatment of PDR K. pneumoniae 186 
Treatment regimens for PDR K. pneumoniae infections were reported in n=11 case series or case 187 
reports, summarized in Table 3. Four studies reported successful use of double-carbapenem 188 
combinations, either alone 5, 57, 68 or combined with colistin, 57, 66 against KPC-producing PDR K. 189 
pneumoniae. Notable is that in 2 of the studies successful clinical and microbiological outcomes 190 
were reported despite high MICs (128-256 mg/L) for carbapenems 5, 68 and the synergism was 191 
confirmed in vitro with time-kill assays. 68 Other effective treatment regimens were 192 
ceftazidime/avibactam 53, 63, 64 and high dose (200mg once daily) tigecycline combined with 193 
colistin and amikacin, a synergistic combination in vitro 69 (Table 3).  194 
Treatment of PDR P. aeruginosa 195 
Reports of successful treatment regimens against infections caused by PDR P. aeruginosa 196 
included; ceftolozane/tazobactam (C/T) in a patient with ventilator-associated pneumonia, 60 197 
high-dose intravenous (IV) amikacin (25-50mg/kg) in one patient with intraabdominal infection 198 
and one patient with pneumonia (amikacin MIC 16mg/L), 70 and high-dose intraventricular 199 
amikacin in a case of ventriculitis (amikacin MIC=32mg/L). 58 Notable is that both patients 200 
treated with high-dose IV amikacin had renal failure and continuous venovenous 201 
hemodiafiltration was concomitantly performed to prevent amikacin nephrotoxicity, allowing 202 
trough concentrations below 5 to 10 mg/L. 70  203 
Synergistic combinations may also be useful according to two studies. 73, 75 Amikacin (1g/day) 204 
with meropenem (2g q8h infused over 3 hours) resulted in both microbiological and clinical 205 
success in 4 cases of ventilator-associated pneumonia. 73 The combination was confirmed to be 206 
synergistic in vitro. 73 However, all isolates were intermediately susceptible to both amikacin 207 
(MIC 16mg/L) and meropenem (MIC 8mg/L), 73 and the high dose prolonged infusion of 208 
meropenem may explain the efficacy of the regimen. 85 In another case series, 4 of the 5 209 
patients with various infections were cured (both microbiological and clinical cure), 3 of which 210 
were treated with different potentially synergistic colistin-based combinations. 75 However, 211 
synergism was not confirmed. 75 212 
Treatment of PDR A. baumannii 213 
We found only one case series regarding the treatment of PDR A. baumannii. 4 In 10 patients 214 
with ventilator-associated pneumonia, the combination of IV colistin, high-dose IV tigecycline 215 
(200 mg loading dose followed after 12 h by 100 mg q12h), high-dose IV ampicillin/sulbactam 216 
(6/3g q8h) and inhaled colistin resulted in clinical success in 9 patients and microbiological 217 
eradication in 7. 4 All patients were concurrently receiving empirical MRSA coverage (linezolid 218 
n=8, vancomycin n=1, ceftaroline n=1), an important consideration as synergism between 219 
colistin and these agents has been described. 86-88 220 
Treatment of other PDR GNB 221 
The combination of ceftazidime/avibactam (MIC=16mg/Lぶ ヮﾉ┌ゲ ﾏWヴﾗヮWﾐWﾏ ふMIC д ヲヵヶ ﾏｪっLぶ 222 
plus high doses of nebulized colistin, successfully treated a post-transplant cystic fibrosis patient 223 
with PDR bacteremic Burkholderia cepacia infection. 55 Ceftazidime/avibactam was synergistic in 224 
vitro with meropenem, 55 which is in agreement with another case report in PDR K. pneumoniae. 225 
64 226 
Another case series of ICU patients with bloodstream or urinary tract infections by PDR 227 
Providencia stuartii, evaluated the combination of piperacillin/tazobactam (4.5 g q8h) plus 228 
amikacin (1 g q24h), a synergistic combination in vitro. 65 Follow-up cultures were sterile in all 229 
but one patient, but mortality was high (6 of the 10 patients with bacteremia and 1 of the 5 230 
patients with urinary tract infection died). 65  231 
In vitro activity of newer agents 232 
In vitro activity of newer agents against PDR isolates was reported in few studies; 233 
Ceftolozane/tazobactam (C/T) was active against all 7 PDR P. aeruginosa isolates in 3 studies, 12, 234 
42, 60 whereas all 14 isolates in 4 other studies were resistant to C/T. 10, 31, 83, 89 235 
Aztreonam/avibactam was active against 2 PDR and all XDR (n=111) Enterobacteriaceae in one 236 
study. 23 Ceftazidime/avibactam was active against selected PDR strains based on case-reports 237 
(n=4 KPC-producing K. pneumonia, 53, 59, 63, 64, n=1 Burkholderia cepacia 55). 238 
Meropenem/vaborbactam was not active against the single PDR isolate (Providencia stuartii) in 239 
one study. 27 Finally, plazomicin was  initially reported to have good activity (MICг2mg/L) against 240 
8 of 9 PDR Enterobacteriaceae in a study in Greece, 45 but in a subsequent study in the same 241 
region, 7 of 17 PDR K. pneumonia isolates were highly resistant to plazomicin (MIC>256mg/L), 242 
ﾐЭΑ ┘WヴW ゲ┌ゲIWヮデｷHﾉW ふгヲﾏｪ/L) and n=3 had an MIC of 4mg/L. 11 243 
 244 
Summary of main findings 245 
Despite the rarity of pandrug resistance, reviewed studies reflected an increasing worldwide 246 
dissemination of PDR GNB in at least 25 countries in 5 continents.  PDR GNB were mostly 247 
reported in ICU patients but significant outbreak potential and dissemination was 248 
demonstrated, including international spread. Among PDR pathogens detected by this review A. 249 
baumannii, K. pneumonia and P. aeruginosa were the most common species reported as PDR, 250 
whereas PDR E. coli remain exceedingly rare. 251 
All-cause mortality in patients with PDR GNB infection is high. Although the extent of 252 
attributable mortality was unclear, reviewed studies indicated that mortality might be 253 
substantially reduced by treatment regimens active in vitro. Newer agents, such as 254 
ceftolozane/tazobactam, ceftazidime/avibactam and plazomicin, appear to be active against 255 
some GNB strains resistant to all older antimicrobials. 11, 12, 42, 45, 53, 59, 60, 63, 64 However, strains 256 
pan-resistant even to the newer agents have been reported. 10, 11, 31, 45, 83, 89 Other options for the 257 
treatment of PDR GNB infections include synergistic combinations 4, 5, 55, 57, 65, 68, 69, 73, 75 and 258 
increased exposure treatment regimens to achieve pharmacokinetic/pharmacodynamic (PK/PD) 259 
targets. 58, 70 However, current evidence remains limited, the risk of bias is high and head-to-260 
head trials of different treatments are lacking. 261 
Synergistic combinations for PDR infections 262 
Several synergistic combinations have been successfully used in PDR GNB infections, such as 263 
double-carbapenem 5, 57, 68 or double-carbapenem with colistin 57, 66 for KPC-producing K. 264 
pneumoniae, ceftazidime/avibactam with carbapenems for K. pneumoniae 64 and Burkholderia 265 
cepacia, 55 and high-dose ampicillin/sulbactam with meropenem and colistin for A. baumannii. 4, 266 
90, 91 Notable is that neither double-carbapenem nor ceftazidime/avibactam are active against 267 
metallo-é-lactamases (MBLs). This has important implications considering that a significant 268 
percentage of carbapenem-resistant isolates in some areas are MBL-producers 11, 92-94. In 269 
contrast, the combination aztreonam/avibactam can restore activity against MBL-producing 270 
isolates, 95, 96 since aztreonam is not hydrolyzed by MBLs and avibactam effectively inhibits other 271 
beta-lactamases (including ESBLs, KPC and OXA-48) therefore restoring the activity of 272 
aztreonam. Aztreonam/avibactam is not currently available, however the combination of 273 
ceftazidime/avibactam plus aztreonam has been used successfully against infections by MBL-274 
producing bacteria. 97-99 275 
Other less studied combinations may also be useful. Notable is the in vitro synergy of colistin 276 
with agents such as linezolid, vancomycin and teicoplanin in colistin-resistant GNB strains. 86, 87 277 
Fosfomycin combined with meropenem also appears promising and high cure rates (7 of 10 278 
patients) have been reported even for fosfomycin-resistant isolates. 100 Despite the availability 279 
of several in vitro studies on synergistic combination, in vivo studies, such PK/PD and outcome 280 
studies, are lacking. 101 281 
Revival of old antibiotics 282 
The emergence of MDR/XDR bacteria has led to the revival of older antibiotics, with colistin 283 
being a good example. 102 In PDR infections, colistin is often used in synergistic combinations 284 
with other antibiotics. 4, 57, 66, 72 Nebulized colistin, allowing higher epithelial lining fluid 285 
concentrations than IV colistin, 103, 104 may be useful for PDR respiratory infections and has been 286 
used as part of synergistic combinations. 4 However, data on PDR infections to allow comparison 287 
of inhaled versus IV colistin are lacking. Based on the available data from colistin-susceptible 288 
infections, adding nebulized colistin to IV colistin has been associated with improved outcomes 289 
105-107 and the efficacy of nebulized colistin (without concomitant IV colistin) either as 290 
monotherapy or in combination with other antibiotics has been found similar to IV colistin and 291 
has been associated with lower nephrotoxicity. 108, 109 292 
Another old antibiotic of renewed interest is IV fosfomycin. Although largely unavailable outside 293 
Europe, IV fosfomycin appears to be an effective treatment options for antibiotic-resistant 294 
Enterobacteriaceae, 110, 111 and has been used successfully for infections resistant to all other 295 
options. 101, 112 However, we noted a lack of reporting of fosfomycin susceptibility in several 296 
studies in this review (Supplementary Table 4). Furthermore, there are concerns regarding the in 297 
vivo activity of fosfomycin against P. aeruginosa (even when susceptible in vitro) and the risk of 298 
emergence of resistance during treatment. 113 Minocycline has also been proposed as an option 299 
for resistant bacteria 114 but susceptibility data for minocycline was not reported in most of the 300 
reviewed studies (Supplementary Table 4). To guide the use of these old antimicrobials in 301 
clinical practice more evidence is required from modern PK/PD studies and randomized 302 
controlled trials. 102, 115, 116  303 
Reconsideration of the PDR definition 304 
Until recently, isolates with intermediate susceptibilities were interpreted as non-susceptible. 8 305 
In 2019, EUCAST replaced the term intermediate with susceptible, increased exposure to 306 
indicate that there is high likelihood to achieve therapeutic success by increasing exposure to 307 
the antimicrobial. For example, high-dose prolonged infusion meropenem may be effective for 308 
K. pneumoniae with MIC 4-8mg/L. 85 Additionally, two studies on PDR P. aeruginosa infection 309 
demonstrated successful treatment using higher doses of amikacin. 58, 70 Another point to 310 
consider when defining PDR is the potential synergism between agents that are inactive alone 311 
but active when used in combination. 312 
Limitations 313 
Reported PDR proportions in this review may be overestimated because we excluded studies 314 
reporting no PDR isolate and because the list of antimicrobials tested for susceptibility was 315 
incomplete in several studies (Supplementary Table 4). In contrast, the use of methods other 316 
than broth microdilution for the evaluation of susceptibility to colistin may result in 317 
underestimation of the proportion PDR because these methods result in a high rate of false 318 
susceptibility.  117, 118  319 
Furthermore, although our findings indicate the worldwide spread of PDR GNB, they do not 320 
accurately reflect their geographical distribution. Most non-eligible studies originate from Asia, 321 
mainly from China (Supplementary Tables 5 and 6), resulting in underrepresentation of these 322 
areas in this review. Additionally, we cannot exclude the possibility of over-reporting or under-323 
reporting PDR GNB in some countries.  324 
Finally, despite our efforts to decrease language bias using Google Translate, data extraction 325 
could be inaccurate. 119 Nevertheless, for studies requiring full-text review using Google 326 
Translate we believe that their exclusion was reliable as it was based on the list of agents used 327 
for susceptibility testing. 328 
Conclusions 329 
PDR GNB isolates are increasingly being reported worldwide and several studies have 330 
demonstrated their potential for intra- and inter-institutional and even international 331 
dissemination. All-cause mortality following PDR GNB infection appears to be high irrespectively 332 
of the infecting organism, but the extent to which mortality is attributable to the infection 333 
remains unclear. Despite the lack of controlled trials several treatment regimens have been 334 
reported to be effective against PDR GNB infections and the reviewed studies indicated that 335 
mortality might be substantially reduced by treatment regimens active in vitro. These include 336 
newer agents and increased exposure regimens, but most studies reporting successful 337 
treatment of PDR GNB infections used synergistic combinations. Synergistic combinations are 338 
often the only treatment option for PDR GNB infections and therefore more research is 339 
required, including PK/PD and outcome studies. Considering the rarity of the PDR GNB, multi-340 
center studies are necessary. 341 
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* See Supplementary Figure 1 for the flow chart of the review of non-English literature 
# Summarized in Supplementary Tables 5-7 
Records retrieved through 
database search (n=670 from 
Medline, n=987 from Scopus) 
Remaining records after 
removal of duplicates 
(n=1020) 
Remaining records after 
screening by title and/or 
abstract (n=401) 
Excluded based on the title/abstract (n=619) 
Studies included in the review 
(n=70) 
• Studies not reporting any PDR isolates 
(n=69) 
• Non-eligible studies reporting PDR 
isolates (n=212)#:  
o Missing susceptibility testing for 
major antimicrobial groups (n= 
126) 
o Not reporting the list of 
antimicrobials tested (n=26) 
o Using the term PDR for isolates 
susceptible to at least one 
antibiotic (n=60) 
• No access to full-texts (n=45) 
o non-English articles (n=42) * 
• Duplicate studies reporting the same 
PDR isolates (n=5) 
Studies included from additional sources: 
• n=7 were retrieved by the additional 
search of the newer antimicrobials  
• n=4 were retrieved from the references 
of included articles 
Table 1; Geographical distribution of pandrug-resistant isolates by 
species 







Total 526* 172 125 175* 54 
Europe 280 107 71 80 22 
Greece 181 100 47 17 Providencia stuartii n=16 
Enterobactereaceae not 
specified n=1 
Spain 50 5 1 43 Burkholderia cepacia n=1 
Italy 15 1 9 5 0 
France 13 0 7 4 Burkholderia cepacia n=2 
Slovakia 8 0 0 8 0 
Germany 3 1 0 0 Serratia marcescens n=2 
Belgium 2 0 0 2 0 
Serbia 1 0 0 1 0 
Netherlands 6 0 6 0 0 
Portugal 1 0 1 0 0 
Americas 24 2 12 8 2 
United  
States 
9 0 5 2 Enterobacteriaceae not 
specified n=2 
Brazil 12 2 7 3 0 
Mexico 2 0 0 2 0 
Canada 1 0 0 1 0 
Asia 180 63 41 52 24 
India 101 11 28 40 22 # 
Turkey 11 1 7 1 Enterobacteriaceae not 
specified n=2 
Russia 3 3 0 0 0 
Pakistan 29 19 2 8 0 
Iran 18 17 0 1 0 
Thailand 12 12 0 0 0 
United Arab 
Emirates 
4 0 4 0 0 
Taiwan 1 0 0 1 0 
Japan 1 0 0 1 0 
Australia 35 0 1 34 0 
Australia 35 0 1 34 0 
Africa 6 0 0 0 6 
South Africa 6 0 0 0 Serratia marcescens n=6 
* The source (country) of one PDR P. aeruginosa isolate from a multi-center study was not 
reported.42  
# E. coli n=1, Enterobacter spp n=6, Burkholderia spp n=3,  Elizabethkingia meningoseptica n=3,  
Chryseobacterium indologenes n=5,  Morganella morganii n=2, unclear n=2
Table 2; All-cause mortality1 of patients with pandrug-resistant infections by bacterial species and 
site of infection2 
 Percentage of deaths (number of deaths/ total number of patients) 
 All sites  BSI3 RTI4 UTI without BSI CNS5 Osteomyelitis IAI6 
Total 53% (75/142) 50% (21/42) 44% (19/43) 23% (3/13) 75% (3/4) 67% (2/3) 50% (1/2) 
Pseudomonas 
aeruginosa 
58% (30/52) 56% (5/9) 31% (4/13) 0% (0/1) 50% (1/2) No data 0% (0/1) 
Klebsiella 
pneumoniae 
47% (16/34) 31% (5/16) 50% (1/2) 29% (2/7) 100% (1/1) 67% (2/3) 100% (1/1) 
Acinetobacter 
baumannii 
56% (20/36) 71% (5/7) 50% (14/28) No data 100% (1/1) No data No data 
Providencia 
stuartii 
47% (7/15) 60% (6/10) No data 20% (1/5) No data No data No data 
1Mortality was variably defined in included studies (28- or 30-day mortality, mortality up to discharge from the ward, mortality up to discharge 
from the hospital). 2 In some studies it was not possible to extract data for each site of infection. 3 Bloodstream infections (BSI) including; 
primary BSI, catheter-related BSI, BSI secondary to UTI (urinary tract infection) and BSI secondary to cellulitis. 4 Respiratory tract infections (RTI) 
including pneumonia and ventilator-associated pneumonia. 5 Central nervous system infections (CNS), 6 Intraabdominal infections (IAI)
Table 3; Studies of treatment options for PDR K. pneumoniae 




























Oliva A et al 
2014 68 
Case series of 3 
patients in Italy with 
BSI. 
Case 1 and 3: 2 g of meropenem q8h plus 
1 g of ertapenem q24h. Case 2: 500 mg of 
ertapenem q24h and 1 g of meropenem 
q12h (doses adjusted to creatinine 
clearance).  
Case 1: "complete recovery" after 21 
days of treatment. Case 2: The patient 
became afebrile after 48 h of treatment 
and blood cultures were sterile. 
However, he died 2 days later due to 
acute heart failure. Case 3: complete 
recovery after 24 days of treatment. 
Souli M et 
al 2017 5 
Case series of 14 
patients in Greece. UTI 
n=3, sBSI due to UTI 
n=2, sBSI due to PN 
n=1, BSI n=5, VAP n=1, 
CRBSI n=1, EVD n=1. 
1 g of ertapenem (1-hour infusion) q24h 
administered 1 h prior to the first dose of 
meropenem which was given at a dose of 
2 g q8h (3-hour infusion) or equivalent 
renally adjusted doses. 
Clinical and microbiologic outcome was 
evaluated on days 14 and 28 and 
patients were followed up to discharge. 
n=11 responded clinically and n=10 
responded both clinically and 
microbiologically. n=9 were alive at last 
follow-up. 
Oliva A et al 
2015 66 
Case report of a 
bloodstream infection 
(both urine and central 
venous catheter 
cultures were also 
positive). Italy. 
ertapenem 1 g/day + meropenem 2 g q8h 
+ IV colistin (loading 6 MIU, then 4,5 MIU 
q12h). The triple combination 
(ertapenem, meropenem, colistin) was 
found to be more rapidly bactericidal 
compared to double-carbapenem alone 
in time-kill assays. 
After 96 h she became afebrile. 
Laboratory analyses showed a reduction 
of the ESR and CRP. Blood and urine 
cultures did not grow any organism.  
The patient was discharged after 14 days 
Emre S et al 
2018 57 
Report of 2 patients in 
Turkey. One with soft 
tissue infection and 
one with catheter 
related bacteremia. 
Case 1: meropenem 1g x3 + ertapenem 
1g x1 + colistin 9 MIU loading dose 
followed by 4.5 MIU q12h. Case 2:  
meropenem 1g x3 + ertapenem 1g x1 
In both patients repeat cultures were 
sterile. The first patient died at day 32 
(not attributable to the infection). The 

























Parruti G et 
al 2019 53 
Case report. Italy. 
Recurrent bacteremia 




The final regimen included: 
ceftazidime/avibactam (2g/8h), 
tigecycline (loading 100mg then 
50mg/12h), meropenem (2g/8h), 
gentamycin (loading 7mg/kg, then 
5mg/kg/24h) 
Repeated recurrences despite transient 
response and removal of the prosthetic 
material. The patient finally responded 




CL et al 
2016 63  
Case report from 
Australia. Severe 
pancreatitis 
complicated by IAI by 
PDR K. pneumoniae 
Ceftazidime/avibactam (plus 
metronidazole and teicoplanin). The 
isolate (KPC2-producing) was susceptible 
in vitro to ceftazidime/avibactam. 
The patient demonstrated a clinical, 
biochemical and radiological response 
with no development of in vitro 
resistance after 6 weeks of treatment. 
However, microbiological clearance 
was not achieved, surgical management 
was not possible, and the patient died 
soon. 
Camargo JF 
et al 2015 64 
Case report from USA. 
BSI. Also isolated from 
urine at >105 CFU/mL 
and the central venous 
catheter tip (>102 
CFU/mL). 
Ceftazidime/avibactam (1g/250 mg q8h 
and ertapenem (1 g q24h)(doses adjusted 
for creatinine clearance). Of note is that 
the patient had previously failed a triple 
regimen (meropenem, ertapenem, 
colistin). The isolate was susceptible in 
vitro to ceftazidime/avibactam alone and 
synergy was noted with carbapenems. 
The patient responded well, with 
sterilization of blood cultures within 24 
hours. She was discharged from the 

















RM et al 
2010 69 
Case report. USA. CBSI. 
MICs: colistin >8mg/L, 
carbapenems >16mg/L, 
amikacin 32 mg/L, 
tigecycline 2mg/L 
IV (10.5 MIU q24h) and inhaled (2.25 MIU 
q12h) colistin, high-dose tigecycline (200 
mg IV daily) and IV amikacin (500 mg 
q12h for 10 days). Of note is that the 
patients had not responded to a 
combination regimen including standard 
dose tigecycline (50mg twice daily). Both 
tigecycline + amikacin and tigecycline + 
colistin were found to be synergistic in 
checkerboard assays. 
The patient improved clinically and was 
discharged after 75 days. The 
bacteremia resolved but the patient 
remained colonized (rectal swab and 
sputum cultures) 
Trevino M 
et al 2011 49 
Case report (only n=1 
PDR infection). Spain. 
Bacteremia. 
Case 1: First tigecycline 50mg q12h 
(MIC=1mg/L). Then fosfomycin 4g q8h 
(MIC=192mg/L) + amikacin 500mg q12h 
(MIC=32mg/L).  
Failure and still in hospital 
Alho AC et 
al 2019 52 
Case report. Portugal. 





Colistin 5 MIU q12h (dose increased from 
4 MIU which had been given for 12 days), 
tigecycline 200mg loading followed by 
100mg q12h, meropenem 2g q8h, 
amikacin 1g q24h. MICs were not 
reported.  
The patient died with persistent 
bacteremia 
Elemam A 
et al 2009 71 
Case report. USA.  
Case 1: catheter-
related UTI. 
Case 2: sBSI associated 
with a post-Whipple 
hepatic abscess 
Case 1: catheter removal and tigecycline 
for 10 days (MIC>8mg/L). 
Case 2: abscess drainage and tigecycline + 
colistin  
(doses not reported) 
 
Case 1: Persistent dysuria at discharge. 
Spontaneous resolution of symptoms 
but persistent bacteriuria 1 year later 
Case 2: Died of septic shock at day 14 
BSI= bloodstream infection, CRBSI=catheter-related bloodstream infection, CRP= C-reactive protein, ESR= erythrocyte sedimentation rate, 
EVD=external ventricular drainage, IAI= intraabdominal infection, MIU= million international units, IV= intravenous, PN= pneumonia, sBSI= 
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Supplementary Figure 1; Flowchart for the non-English literature 
 
*Such as reviews and commentaries not providing original data. **Summarized in 
Supplementary Tables 5-7. PDR=pandrug resistant 
After de-duplication n=235 
non-English records were 
retrieved 
n=2 were included in the 
review [1, 2] 
• Irrelevant/non-original* n=96 (French 
n=49, Chinese n=18, German n=14, Russian 
n=3, Spanish n=3, Hungarian n=3, Korean 
n=2, Italian n=1, Japanese n=1, Polish n=1, 
Norwegian n=1) 
• No access to full-text n=42 (Chinese n=40, 
Russian n=1, Polish n=1) 
n=97 full-texts were 
evaluated (with Google 
Translate) 
• Reporting zero PDR isolates or not-reporting 
the number of PDR isolates n=19 (Chinese n=9, 
French n=4, Spanish n=3, Turkish n=2, Polish 
n=1) 
• Non-eligible list of antimicrobials to define 
PDR n=76** (Chinese n=66, Turkish n=4, 



















Type of infection Pathogens studied1 
Del Barrio-
Tofiño E 2019 
[3] 
2017 Spain Multicenter Mixed 51 hospitals Clinical isolates P. aeruginosa 
Galani I 2019 
[4] 2014-
2016 
Greece Multicenter Unclear 












Italy Single center Mixed 
Cystic fibrosis 
center 




Le Page 2019 
[6] 2014-
2016 




E. coli,  
K. pneumoniae,  
P. aeruginosa,  
A. baumannii 







Multicenter Inpatients 12 Hospitals VAP P. aeruginosa 









P. aeruginosa,  
A. baumannii,  
S. maltophilia,  

















Type of infection Pathogens studied1 
Álvarez-








infections (VAP, CRBSI, 
CAUTI)  
P. aeruginosa 












India Multicenter Unclear Tertiary hospitals Clinical isolates P. aeruginosa 




Brazil Single center Unclear Tertiary hospital Bacteremia 
polymyxin-resistant K. 
pneumoniae 





Turkey Single center Inpatients 
5 large ICUs of a 
university 
hospital 
ICU-acquired infections Gram-negative 




Greece Single center Inpatients 
Intensive care 
unit 
bacteremia with sepsis XDR A. baumannii 
Mohapatra et 




India Single center Unclear Tertiary hospital Clinical isolates Gram-negative 
Pedersen T et 












Sader HS et al 



























Type of infection Pathogens studied1 
Aguilar-Rodea 





Mexico Single center Inpatients 
Pediatric tertiary 
hospital 
Nosocomial infections P. aeruginosa 



























Multicenter Mixed 82 hospitals Clinical isolates Gram-negative  










K. pneumoniae,  
E. coli,  
P. aeruginosa,  
B. cepacia,  
A. baumannii 
 
Pfaller MA et 





























Type of infection Pathogens studied1 
Turkey 
and Israel 

















pneumonia, skin and 
skin structure 
infections, urinary tract 
infections, intra-
abdominal infections, 
and other types of 
infections 
P. aeruginosa 




Iran Single center Mixed 
University 
hospital 
100 randomly selected 
clinical isolates 
carbapenem-resistant   
A. baumannii 
Bathoorn E et 
al 2016 [27]  
2013-
2014 
Greece Multicenter Inpatients 3 hospitals 
Randomly selected 
clinical isolates 
KPC K. pneumoniae 




Iran Multicenter Unclear 
University 
hospital 
Clinical isolates P. aeruginosa 




Greece Single center Inpatients 
Intensive care 
unit 
VAP XDR A. baumannii 









Thailand Single center Inpatients 
Intensive care 
unit 
















Type of infection Pathogens studied1 
Kulkova N et 















Greece Single center Unclear 
University 
hospital 
Clinical isolates A. baumannii 





Pakistan Multicenter Inpatients 
ICU, medical and 
surgical wards of 
3 healthcare 
facilities 
Clinical isolates A. baumannii 
Mizutani T et 




Japan Multicenter Unclear 14 Hospitals Clinical isolates P. aeruginosa 
Nasrolahei M 
et al 2014 
[35] 
 
2013 Iran Single center Inpatients 
Tertiary burn and 
ICU center 
Clinical isolates A. baumannii 
















et al 2014 
[37] 
2013 India Single center Inpatients 
Pediatric 
oncology 
Febrile neutropenia Any 


























Type of infection Pathogens studied1 
Japoni-Nejad 
A et al 2013 
[39] 
2011 India Single center Inpatients 
Intensive care 
unit 
Clinical isolates during 
an outbreak 
A. baumannii 













Jácome PR et 




Brazil Multicenter Inpatients 
5 teaching 
hospitals 
Clinical isolates P.aeruginosa 
Gill M et al 
2011 [42] 
2010 Pakistan Single center Unclear Military hospital Clinical isolates P. aeruginosa 
Mahajan G et 
al 2011 [43] 
2010-
2011 
India Single center Unclear Tertiary hospital 
Clinical isolates from 
urine, pus/wound swab, 
endotracheal 
secretions, sputum, 
body fluids, and blood 
A. baumannii 
Treviño M et 
al 2011 [44] 
2009-
2010 








Arroyo LA et 
al 2009 [45] 
2000-
2006 
Spain Single center Unclear Tertiary hospital Clinical isolates Colistin-resistant 
Mukhopadhy





India Single center Unclear 
University 
hospital 
Clinical isolates P. aeruginosa 
Abbreviations: CAUTI= catheter-associated urinary tract infection, CRBSI= catheter-related bloodstream infection, GNB= Gram-negative 
bacteria, ICU= intensive care unit, VAP= ventilator-associated pneumonia 
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1Data were extracted only for eligible pathogens based on our review criteria, i.e. PDR Gram-negative bacteria with susceptibility testing 
available for all the major antimicrobials (including carbapenems, polymyxins, aminoglycosides and tigecycline). 
















Alho AC et al 2019 
[47] 
Unclear Portugal Case report ICU BSI-
osteomyelitis 
K. pneumoniae No Yes 
Assimakopoulos SF 
et al 2019 [48] 
 
Unclear Greece Case-series 
(n=10) 
 
ICU VAP A. baumannii No Yes 








K. pneumoniae No Yes 
Abat et al 2018 [8]4 2009-
2015 




RTI B. cepacia Unclear No 
Agarwal S et al 
2018 [50] 
Unclear India Case series 
(n=2) 
ICU CRBSI, VAP C. indologenes Unclear Yes 
Cantón-Bulnes ML 
et al 2018 [51] 
Unclear Spain Case report Cystic fibrosis 
setting 
RTI B. cepacia No Yes 
De Man TJB et al 
2018 [52] 
2016 USA Case report Hospital Osteomyelitis K. pneumoniae No Yes 
Emre S et al 2018  
[1] 
(Turkish) 
Unclear Turkey Case series 
(n=2) 
Prior ICU stay STI, CRBSI K. pneumoniae Yes (1 of the 2 
cases) 
Yes 




Greece Case series 
(n=7) 
ICU BSI A. baumannii No No 
Molinaro M et al 
2018 [53] 





















China Case report 
(n=1 PDR) 
Hospital Meningitis A. baumannii No Yes 
Aires CAM et al 
2017 [54] 
2011 Brazil Case report Hospital UTI K. pneumoniae No No 
Alvarez Lerma F et 
al 2017 [55] 
2017 Spain Case series 
(n=2) 
ICU VAP P. aeruginosa No Yes 
Sonnevend Á et al 
2017 [56] 






K. pneumoniae Unclear No 




Greece Case series 
(n=14) 
2 Hospitals Various sites K. pneumoniae Unclear Yes 
Xiong J et al 2017 
[58] 
 
2014 Canada Case report Hospital RTI P. aeruginosa Unclear No 




India Case series 
(n=2) 
Ophthalmology Keratitis P. aeruginosa No Yes 
Mandrawa et al 
2016 [60] 
Unclear Australia Case report ICU IAI K. pneumoniae No Yes 




Greece Case series ICU VAP A. baumannii Yes No 
Camargo JF et al 
2015 [61] 
Unclear USA Case report ICU BSI K. pneumoniae No Yes 
Douka E et al 2015 
[62] 
2011 Greece Case series ICU BSI and UTI P. stuartii Unclear Yes 
Inchai J et al 2015 
(two publications 
from the same 
cohort) [30, 31]4 
2005-
2011 





















Slovakia Case report Hospital BSI P. aeruginosa Yes Yes 
Oliva A et al 2015 
[63] 
Unclear Italy Case report Infectious 
Diseases 
BSI K. pneumoniae No Yes 
Weterings V et al 
2015 [64] 




UTI K. pneumoniae No No 
Oliva A et al 2014 
[65] 
Unclear Italy Case series 
(n=3) 
Hospital BSI K. pneumoniae No Yes 




Spain Case report 
(n=1) 
Hospital BSI K. pneumoniae Unclear Yes 
Humphries RM et 
al 2010 [66] 
2010 USA Case report ICU CRBSI K. pneumoniae No Yes 
Layeux B et al 2010 
[67] 
 
Unclear Belgium Case series 
(n=2) 
ICU IAI, RTI P. aeruginosa Yes (1 of the 2 
patients) 
Yes 




USA Case series 
(n=2) 
Hospital UTI, BSI K. pneumoniae No Yes 





Greece Case series 
(n=2) 
Hospital RTI P. aeruginosa No Yes 
Mukhopadhyay C 
et al 2008 [46]4 
2005-
2007 
India Case series 
(n=24) 
Hospital Not reported P. aeruginosa Unclear Yes 
Mentzelopoulos 
SD et al 2007 [70] 
 
2005 Greece Case series 
(n=5) 
ICU VAP P. aeruginosa Yes Yes 




Slovakia Case series 
(n=7) 
























Greece Case series 
(n=5) 
ICU RTI, UTI, BSI P. aeruginosa Unclear Yes 
Abbreviations: BSI= bloodstream infection, CAUTI= catheter-associated urinary tract infection, CRBSI= catheter-related bloodstream infection, 
GNB= Gram-negative bacteria, IAI= intra-abdominal infection, ICU= intensive care unit, STI= soft tissue infection, VAP= ventilator-associated 
pneumonia 
1 Design regarding the analysis of outcomes and treatment regimens of PDR infections. 
2 Data were extracted only for eligible pathogens based on our review criteria, i.e. PDR Gram-negative bacteria with susceptibility testing 
available for all the major antimicrobials (including carbapenems, polymyxins, aminoglycosides and tigecycline). 
3 Including patients with infection by other pathogen at another site. 





Supplementary Table 3; Studies reporting PDR isolates but without information regarding the 





Country Healthcare setting Type of infection PDR isolates 
Finklea et al 
2018 [73] 
2015 USA Cystic fibrosis clinic Respiratory samples P. aeruginosa 
Leite GC et 
al 2016 [74] 
 
Unclear Brazil Microbiology 
laboratory 
Clinical isolates A. baumannii 
Cassu-Corsi 
D et al 2015 
[75] 
 
2013 Brazil Hospital Urinary isolates K. pneumoniae 
Gruber TM 
et al 2015 
[76] 
2014 Germany Hospital Colonization, UTI S. marcescens 
Zowawi HM 
et al 2015 
[77] 
 
2014 United Arab 
Emirates 
Hospital Urinary isolate K. pneumoniae 
Göttig S et 
al 2014 [78] 
2013 Germany ICU Colonization A. baumannii 
Tsioutis C et 
al 2010 [79] 
2006-2008 Greece Hospital Variable A. baumannii 
Lepsanovic 
Z et al 2008 
[80] 
 







Country Healthcare setting Type of infection PDR isolates 
Hsueh PR et 
al 2005 [81] 
1999-2002 Taiwan Hospital Infection/colonization P. aeruginosa 
Dobbin C et 
al 2004 [82] 
 
1989-2002 Australia Cystic fibrosis center 
Isolates from sputum 
of pre-transplant 
patients with cystic 
fibrosis 
P. aeruginosa 
1 These studies were included for epidemiological purposes (geographical distribution of PDR, types of PDR isolates, source of PDR isolates). 
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Supplementary Table 4; Commonly missing (susceptibility testing not performed or not reported1) 
antimicrobials in studies reporting pandrug-resistant Gram-negative bacteria 
 Number (%) of studies in which susceptibility testing 
was missing or not reported1 
Number (%) of PDR isolates for which susceptibility 













Fosfomycin 13 (39%) 25 (78%)2  Intrinsic 
resistance3 




6 (18%) Intrinsic 
resistance3 
7 (37%) 19 (12%) Intrinsic 
resistance3 
102 (59%) 
Ampicillin/sulbactam4 Not applicable5 Not applicable5 5 (26%) Not applicable5 Not applicable5 111 (65%) 
Minocycline 25 (78%) Intrinsic 
resistance3 
15 (79%) 121 (74%) Intrinsic 
resistance3 
145 (84%) 
Amikacin 5 (15%) 4 (12%) 3 (16%) 29 (18%) 13 (7%) 15 (9%) 
Gentamicin 0 8 (24%) 2 (11%) 0 58 (33%) 19 (11%) 
1 It is possible than in some of the studies susceptibility testing was performed but not reported for some of these antibiotics 
2 Breakpoints for P. aeruginosa for intravenous fosfomycin have not been established and there are concerns about the in 
vivo activity of fosfomycin against P. aeruginosa (even when susceptible in vitro) and the risk of emergence of resistance during treatment [83] 
3 According to EUCAST expert rules 
4 Or cefoperazone/sulbactam 




Supplementary Table 5; Non-eligible studies due to missing 
susceptibility testing for major antimicrobial groups 
First author- Year of publication 




ČｷｪｷﾐゲﾆｷWﾐ_ A Wデ ;ﾉ ヲヰヱΓ [84] Lithuania polymyxins 11 
Los-Arcos I et al 2019 [85] 
 Spain 
carbapenems, tetracyclines and 
trimethoprim-sulfamethoxazole 13 
Varsha M et al 2019 [86] USA tigecycline 7 




Aljanaby AAJ et al 2018 [88] India polymyxins, tigecycline 19 
Bickenbach J et al 2018 [89] 
 Germany polymyxins  
Demoz GT et al 2018 [90] Ethiopia polymyxins, tigecycline 1 
El-Shouny et al 2018 [91] 
 Egypt polymyxins 20 
Gao Q et al 2018 [92] 
(Chinese) * China polymyxins  
Gashaw et al 2018 [93] 
 Ethiopia polymyxins, tigecycline 24 
Guducuoglu et al 2018 [94] 
 Turkey tigecycline 8 
Nuryastuti T et al 2018 [95] Indonesia tigecycline 1 
S;ｬﾏ;ﾆ-Tartar A et al 2018 [96] 
(Turkish)* Turkey tetracyclines, tigecycline  
Shrestha D et al 2018 [97] Nepal polymyxins, tigecycline 1 
Wu HG et al 2018 [98] 
 China polymyxins 42 
Xu T et al 2018 [99] 
(Chinese)* China polymyxins, tigecycline  
Gonçalves GB et al 2017 [100] 
 Brazil polymyxins, tigecycline 3 
Jing C,  Wang C 2017 [101] 
(Chinese) * China polymyxins, tigecycline  
Nowak J et al 2017 [102] Europe tigecycline 20 
Reale M et al 2017 [103] 
 Italy aminoglycosides 27 
Samad A et al 2017 [104] 
 Pakistan polymyxins 3 
Swe Swe-Han K et al 2017 [105] South Africa tetracyclines, tigecycline 7 
Uzoamaka M et al 2017 [106] 
 Nigeria polymyxins, tigecycline  
Kryzhanovskaya OA et al 2016 
[107] Russia tigecycline 2 
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Li X et al 2016 [108] China polymyxins, tigecycline 27 
Lolans K et al 2005 [109] USA polymyxins 1 
Ren G et al 2016 [110] 
 China polymyxins, tigecycline  
Zhang Y et al 2016 [111] 
(Chinese)* China polymyxins 921 
Chen Y et al 2015 [112] 
(Chinese)* China polymyxins 81 
Guo X et al 2015 [113] 
(Chinese)* China tigecycline  
He L et al 2015 [114] 
(Chinese)* China polymyxins, tigecycline  
Hu F et al 2015 [115] 
(Chinese)* China polymyxins, tigecycline  
Kim Y et al 2015 [116] South Korea tetracyclines, tigecycline 1 
Lobo LJ et al 2015 [117] 
 USA polymyxins, tigecycline 14 
Murugan N et al 2015 [118] India polymyxins  
Pei HH et al 2015 [119] 
(Chinese)* China polymyxins, tigecycline  
Qiang X et al 2015 [120] 
(Chinese)* China polymyxins, tigecycline  
Qin H et al 2015 [121] 
(Chinese)* China polymyxins, tigecycline 63 
Shao C et al 2015 [122] 
(Chinese)* China polymyxins, tigecycline  
Shapoval SD et 2015 [123] 
(Russian)* Ukrain polymyxins 13 
Tian L et al 2015 [124] 
(Chinese)* China polymyxins, tigecycline  
Anvarinejad M et al 2014 [125] Iran polymyxins 35 
Han X et al 2014 [126] China polymyxins, tigecycline 6 
Han X et al 2014 [127] 
(Chinese) * China polymyxins, tigecycline 6 
Hong-Li Tan et al 2014 [128] China polymyxins 1 
Li-wan W et al 2014 [129] 
(Chinese)* China tigecycline 42 
Moroh JLA et al 2014 [130] Cote d'Ivoire carbapenems, tigecycline 70 
Rajkumari N et al 2014 [131] 
 India polymyxins 847 
Ranjan S et al 2014 [132] 
 India polymyxins 7 
Reddy R et al 2014 [133] India tetracyclines, tigecycline 4 
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Shen Z et al 2014 [134] 
(Chinese)* China polymyxins, tigecycline  
Singh et al 2014 [135] 
 India tetracyclines, tigecycline 18 
Viswanathan R et al 2014 [136] India polymyxins, tigecycline 5 
Garbati MA et al 2013 [137] 
 Saudi Arabia polymyxins 1 
Liu Y et al 2013 [138] 
(Chinese)* China polymyxins, tigecycline 12 
Movahedi Z et al 2013 [139] 
 Iran polymyxins 11 
Shi H et al 2013 [140] 
(Chinese)* China polymyxins 108 
Shi W et al 2013 [141] China polymyxins, tigecycline 5 
Sivaranjani V et al 2013 [142] 
 India polymyxins 15 
Wang Q et al 2013 [143] China polymyxins, tigecycline 3 
Yang J et al 2013 [144] 
(Chinese)* China polymyxins 20 
Zhang H et al 2013 [145] 
(Chinese)* China polymyxins, tigecycline 1635 
Zhang Y et al 2013 [146] China tigecycline 25 
Zhu D et al 2013 [147] 
(Chinese)* China polymyxins, tigecycline 860 
Zhu R et al 2013 [148] 
(Chinese)* China polymyxins, tigecycline 119 
Arduino SM et al 2012 [149] Argentina tetracyclines, tigecycline 5 
Chen Z et al 2012 [150] 
(Chinese)* China polymyxins, tigecycline 8 
Li B et al 2012 [151] China polymyxins, tigecycline 4 
Manageiro V et al 2012 [152] Portugal polymyxins  
Park HJ et al 2012 [153] South Korea polymyxins, tigecycline 234 
Xu J et al 2012 [154] China polymyxins, tigecycline  
Yong-Qiang H et al 2012 [155] 
(Chinese)* China polymyxins, tigecycline  
Zhang Y et al 2012 [156] 
(Chinese*) China polymyxins 86 
Zhu D et al 2012 [157] 
(Chinese)* China polymyxins, tigecycline  
Zhuo C et al 2012 [158] 
(Chinese)* China polymyxins, tigecycline 223 
Babu KVY et al 2011 [159] India polymyxins, tigecycline 35 
Ben RJ et al 2011 [160] Taiwan polymyxins, tigecycline  
19 
 
First author- Year of publication 




Chen Z et al 2011 [161] China tigecycline  
Huiming X et al 2011 [162] 
(Chinese)* China polymyxins, tigecycline 1058 
Li H et al 2011 [163] 
(Chinese)* China polymyxins, tigecycline  
Su D et al [164] 
(Chinese)* China polymyxins, tigecycline  
Zhu D et al 2011 [165] 
(Chinese)* China polymyxins, tigecycline 1037 
Jian C et al 2010 [166] 
(Chinese)* China polymyxins, tigecycline 188 
Joung MK et al 2010 [167] South Korea polymyxins, tigecycline 18 
Pang XL et al 2010 [168] 
(Chinese)* China polymyxins 8 
Sengstock DM et al 2010 [169] USA polymyxins, tigecycline 56 
Wang F et al 2010 [170] 
(Chinese)* China polymyxins, tigecycline 882 
Zhang X et al 2010 [171] 
(Chinese)* China polymyxins, tigecycline 709 
Zhang Y et al 2010 [172] 
(Chinsese)* China polymyxins 84 
Zhu D et al  2010 [173] 
(Chinese)* China polymyxins, tigecycline 634 
Zhuo C et al 2010 [174] China polymyxins, tigecycline 111 
Chuang YY et al 2009 [175] Taiwan polymyxins, tigecycline 11 
Sun J et al 2009 [176] 
(Chinese)* China polymyxins 128 
Taherikalani M et al 2009 [177] Iran aminoglycosides 7 
T;ズH;ﾆ;ﾐ MS Wデ ;ﾉ ヲヰヰΓ [178] 
(Turkish)* Turkey polymyxins, tigecycline 9 
Valencia R et al 2009 [179] Spain tigecycline 12 
Wang F et al 2009[180] 
(Chinese)* China polymyxins, tigecycline 453 
Xiao SC et al 2009 [181] China aminoglycosides, tigecycline 1 
Zhu DM et al 2009 [182] 
(Chinese)* China polymyxins, tigecycline 251 
Zhu J et al 2009 [183] China polymyxins, tigecycline 1 




Wang F et al 2008 [185] 
(Chinese)* China polymyxins, tigecycline 543 
Zhu DM et al 2008 [186] 
(Chinese)* China polymyxins, tigecycline 219 
Chan PC et al 2007 [187] Taiwan polymyxins, tigecycline 9 
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Hadjiliadis D et al 2007 [188] USA polymyxins 45 




Ni YX 2007 [190] 
(Chinese)* China polymyxins 98 




Sun JY and Ni YX 2007 [192] 
(Chinese)* China polymyxins, tigecycline 656 
Zhu DM et al 2007 [193] 
(Chinese) China polymyxins, tigecycline 158 
Zhuo C et al 2007 [194] 
(Chinese)* China polymyxins, tigecycline 6 
Lee K et al 2006 [195] South Korea polymyxins, tigecycline 318 
Lim YM et al 2006 [196] 
(Korean)* South Korea tetracyclines, tigecycline 12 
Vahaboglu H et al 2006 [197] Turkey polymyxins 9 
Vonberg RP et al 2006 [198] Germany polymyxins, tetracyclines 53 
Wang F 2006 [199] 
(Chinese) China polymyxins, tigecycline 264 
Zhu DM et al 2006 [200] 
(Chinese)* China polymyxins, tigecycline 242 








Tian BW et al 2005 [203] 
(Chinese) * China polymyxins 18 
Vonberg RP et al [204] 
(German)* Germany 
polymyxins, tetracyclines, 
aminoglycosides, tigecycline 108 
Kuo LC et al 2004 [205] Taiwan polymyxins, tigecycline 15 
Marais E et al 2004 [206] South Africa polymyxins, tigecycline  
Hsueh PR et al 2002 [207] Taiwan polymyxins, tigecycline 203 
Malik F et al 2012 [208] Pakistan polymyxins, tigecycline 29 
Tsiodras S et al 2000 [209] USA polymyxins, tigecycline 21 
* Articles evaluated using Google Translate. 
# May include duplicates. In some studies, the exact number of PDR isolates was not reported. 
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Supplementary Table 6; Non-eligible studies due to lack of 
reporting of the list of antimicrobial agents tested 
First author- Year of 
publication Country 
Number of possible 
PDR isolates 
Attia H et al 2019 [210] Egypt 2 
Perdigão Neto et al 2019 
[211] Brazil 13 
Del Prete R et al 2019 [212] Italy 33 
Lay C et al 2019 [213] USA 697 
Chen X et al 2018 [214] China 4 
Moodley K et al 2018 [215] South Africa 7 
Guo Y et al 2017 [216] China 10 
Kimura N et al 2016 [217] USA 508 
Bhatt P et al 2015 [218] India 11 
Dimopoulos G et al 2015 
[219] Greece 4 
Li M et al 2015 [220] 
(Chinese)* China 110 
Merli M et al 2015 [221] Italy 2 
Tuon FF et al 2015 [222] Brazil 5 
Mazi W et al 2014 [223] Saudi Arabia 1 
Savi D et al 2014 [224] Italy 1 
Chen H et al 2013 [225] 
(Chinese)* China 53 
Mai M et al 2013 [226] 
(Chinese)* China 61 
Digoy GP et al 2012 [227] USA 2 
Özkurt Z et ak 2012 [228] Tuerky  
Tabah A et al 2012 [229] Europe 3 
Ran YC et al 2010 [230] China 6 
Apisarnthanarak A et al 2009 
[231] Thailand  
LiPuma JJ et al 2009 [232] USA 20 
Tao C et al 2009 [233] China 16 
Lin GM et al 2008 [234] Taiwan 1 





Supplementary Table 7; Non-eligible studies using the term 
pandrug resistance (or pan-resistant) for isolates susceptible to at 
least one antibiotic 
Kanjanawasri S et al 2018 
[236] 
PDR isolates were resistant to all antibiotic groups except 
tigecycline and colistin 
Owrang M et al 2018 [237] All of the isolates were pandrug resistant A. baumannii and the 
lowest resistance rates were observed toward minocycline and 
amikacin (93.33% in both) and trimethoprim/sulfamethoxazole 
(92.38%). 
Rebic V et al 2018 [238] Polymyxin not tested in most isolates. All isolates with 
susceptibility testing to colistin available were susceptible. 
Siddiqui もろ et al 2018 
[239] 
PDR definition: Bacteria resistant to almost all classes of 
antibiotics including polymyxins 
Yi ML et al 2018 [240] All isolates were susceptible to tigecycline 
Alipour N et al 2017 [241] 
 
Colistin-resistant Pseudomonas aeruginosa isolates that were 
all susceptible to alternative antibiotics 
Pan A et al 2017 [242] 
 
All isolates described as PDR were susceptible to collistin 
Chen H et al 2016 [243] 
(Chinese)* 
Case report. K. pneumonieae. Susceptible to tigecycline and the 
patient responded to treatment with tigecycline. 
Li J et al 2016 [244] 
(Chinese)* 
n=3 blaNDM-1 K. pneumoniae isolates. All were susceptible to 
amikacin and polymyxin B. 
Mohamed YF et al 2016 
[245] 
The four bacterial isolates used in this study were confirmed 
to be pan-drug resistant by the antibiotic susceptibility testing 
being resistant to all antibiotic classes except colistin  
Singh SK, Gupta M 2016 
[246] 
 
Carbapenem-resistant-colistin-resistant Klebsiella pneumoniae 
susceptible to tigecycline and cotrimoxazole 
Vourli S et al 2015 [247] A. baumannii. Tigecycline MICs ranged from 0.5 mg/L to 1 
mg/L 
Zhi-Wen Y et al 2015 [248] 
 
The PDR term was used for XDR bacteria 
Iraz M et al 2014 [249] 
 
Pseudomonas aeruginosa susceptible to colistin 
Ning F et al 2014 [250] 
 
Acinetobacter baumannii susceptible to polymyxin 
Dash M et al 2013 [251] 
 
All 8 PDR isolates were susceptible to colistin 
Friedstat JS et al 2013 
[252] 
Pan-resistance is reported in 15 patients, however only one 
instance of colistin resistance was identified. The list of agents 
tested to evaluate for pan-resistance is not reported. 
Liu L et al 2013 [253] 
(Chinese) 
All isolates were sensitive to amikacin 
Qi M et al 2013 [254] Case report of A. baumannii successfully treated with 
tigecycline (pan-resistant to other options) 
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Shao BB, Feng HB 2013 
[255] 
Case report of A. baumannii successfully treated with 
tigecycline (pan-resistant to other options) 
Sun CD et al 2013 [256] 
(Chinese) 
sensitive rate was 100% to polymyxin 
Borcan E et ak 2012 [257] PDR respresents resistance to all antibiotics, except colistin. 
All isolates were susceptible to colistin 
Simsek F et al 2012 [258] Case report. P. aeruginosa susceptible to polymyxin B 
Zhang Z et al 2012 [259] PDR is used to refer to carbapenem-resistant strains. 
Prata-Rocha ML et al 2012 
[260] 
An isolate was deemed pan-resistant if it was resistant to all 
commonly tested antibiotics except colistin 
Kim YJ et al 2011 [261] All PDR Acinetobocter baumannii were susceptible to colistin 
Ning FG et al 2011 [262] PDR P. aeruginosa isolates were resistant to all available 
antibiotics, including third-generation cephalosporin, 
carbapenems and ciprofloxacin, but not polymyxin. Unclear if 
susceptibility testing for aminoglycosides was performed. 
Ozdem B et al 2011 [263] 
(Turkish) 
A. baumannii. All isolates were susceptible to tigecycline. 
Polymyxin testing was not performed. 
Rodrigues AC et al 2011 
[264] 
All samples of pan-resistant P. aeruginosa were sensitive in 
vitro to polymyxin B. 
Saleem AF et al 2011 [265] All PDR Acinetobocter baumannii were susceptible to polymyxin 
Salomon J et al 2011 [266] Case report. P. aeruginosa susceptible only to colimycin. A. 
baumanii susceptible only to colimycin. K. pneumoniae had a 
phenotypic resistance against almost all relevant antimicrobial 
agents except for colistin.  
Sun Z et al 2011 [267] 
(Chinese)* 
There were obvious difference among the drug-resistance 
rates of AB strains to 13 antibiotics (with rates from 42.31% to 
100.00%) i.e. susceptibility to at least one antibiotic was 100% 
 
Tekçe AY et al 2011 [268] Case report of a pan-resistant A. baumannii, susceptible to 
colistin and tigecycline. The patients was successfully treated 
with tigecycline. 
Telang NV et al 2011 [269] Case report. The isolate was only susceptible (moderately) to 
colistin. Tigecycline was not tested. 
Zhao WS et al 2011 [270] Case report of pandrug-resistant Acinetobacter baumannii 
bacteremia. Susceptibility to tigecycline and polymyxins is not 
reported. The patient was successfully treated with tigecycline. 
Glupczynski Y et al 2010 
[271] 
Fifteen of the isolates were found to co-produce ESBLs and 
VIM carbapenemases. These strains were pan-resistant and 
remained susceptible only to colistin (MICs <or= 2 mg/L) 
Huang J et al 2010 [272] All PDR isolates were susceptible colistin 
Sun SM et al 2010 [273] 
(Chinese) 
Case series of 9 patients with infections by pan-drug resistant 
Acinetobacter baumannii. The polymyxin sensitivity were 
100% for these infections 
Werarak P et al 2010 [274] PDR is defined as resistance to all classes of anti-pseudomonas 
antibiotics except polymyxins 
Apisarnthanarak A et al 
2009 [275] 
PDR defined as resistant to all antibiotic classes except 
colistin. + tigecycline was not evaluated 
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Saleem AF et al 2009 [276] Pan-resistance (87/122; sensitive only to Polymyxin) was 
present in 71% of Acinetobacter isolates. 
Apisarnthanarak A 2008 
and 2009 [277, 278] 
PDR A. baumannii was defined as an A. baumannii isolate 
that was resistant to all currently available systemic 
antibiotics, including cephalosporins, aztreonam, 
carbapenems, aminoglycosides, fluoroquinolones, and 
sulbactam (except polymyxin B) 
Arikan Akan O, Uysal S 
2008 [279] 
(Turkish)* 
All K. pneumoniae isolates were susceptible to tigecycline.  5 of 
100 carbapenem-resistant A.baumannii were non-susceptible 
(MIC=3) to tigecycline but concurrent susceptibility to other 
agents (e.g. colistin) is not reported. 
Pinheiro MR et al 2008 
[280] 
PDR defined as resistance to all antibiotics except polymyxin 
Pitout JD et al 2008 [281] No colistin resistance was detected 
Doi Y et al 2007 [282] The PDR isolate was susceptible to colistin 
Fica C A et al 2007 [283]  
(Spanish)* 
PDR defined as resistant to 3rd generation cephalosporins, 
quinolones, aminoglycosides and carbapenems. 
Only 1 isolate was non-susceptible to colistin. 
Tigecycline was not evaluated 
Goverman J et al 2007 
[284] 
Pan-resistance was defined based on susceptibility to the 
following antibiotics: amikacin, gentamicin, tobramycin, 
ceftazidime, meropenem, piperacillin, ticarcillin, and 
ciprofloxacin. All patients with PDR bacteria were treated with 
colistin. 
Jayakumar S, Appalaraju 
B. 2007 [285] 
All of the strains were sensitive to polymyxin 
Kallel H et al 2007 [286] In all patients in this group, A. baumanii and P. aeruginosa 
were PDR and were susceptible only to colistin 
Naas T et al 2007 [287] The PDR isolate was susceptible to colistin 
Peña C et al 2007 [288] All isolates were uniformly susceptible to colistin 
Taccone FS et al 2006 
[289] 
The PDR A. baumannii isolate was susceptible to both colistin 
and tigecycline 
Wang CY et al 2006 [290] All isolates were susceptible to colistin 
Wang H et al 2006 [291] 
(Chinese)* 
All PDR were susceptible to minocycline and colistin 
Deplano A et al 2005 All isolates were susceptible to colistin 
Miriagou V et al 2005 
[292] 
All isolates were susceptible to colistin 
Wang SH et al 2003 [293] Isolates were susceptible to polymyxin B 
Demko CA et al 1998 [294] Panresistant was defined as susceptible to no more than one 
antimicrobial agent. + the list f agents tested is not reported 
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